Privia Health price target raised to $35 from $34 at Canaccord

Canaccord raised the firm’s price target on Privia Health (PRVA) to $35 from $34 and keeps a Buy rating on the shares. The firm said they reported rock solid results for Q4 which beat consensus and believes the company is in a strong position to be opportunistic in business development, either building density in current markets or expand to new markets/states, with an eye toward compounding profitability and cash flow.